Curious about today's AI digest?ai-tldr.dev
Pomegra LogoPomegra

Daily Digest

BriefMarket · mixedMedium impact
Esc

Moderna Stock Jumps 7% Ahead of Cancer Therapy Data

Moderna (press release via Yahoo Finance)2 min read4 sources

Why did Moderna stock jump 7%?

Moderna (MRNA) stock rose about 7% on Monday to about $204 after investors piled in ahead of October 24 cancer vaccine data and its return to the Nasdaq-100 index.

Key numbers

Moderna share price (Oct 5)~$204+6.95%
Year-to-date gain+596%vs ~$22 low in Nov 2025
Market value~$82Bper [2]
Gain since Aug 18+202%per [4]
Citigroup target (Sell)$80per [2]

What happened

Moderna (MRNA) stock rose about 7% on Monday to about $204 after investors piled in ahead of October 24 cancer vaccine data and its return to the Nasdaq-100 index. Moderna and partner Merck said in August that their personalized cancer therapy, given with Merck's Keytruda, helped melanoma patients go longer without their cancer returning than Keytruda alone. Full results will be shown at a medical conference in Madrid on October 24. The stock is up about 596% this year, giving Moderna a value of roughly $82 billion.

Why it matters

Moderna's stock has climbed about 596% in 2026, mostly on hopes that its personalized cancer therapy works, so the October 24 results could move the price sharply either way. Citigroup rates the shares "Sell" with an $80 target, far below today's price, saying the stock looks expensive for the sales expected. Index funds must also buy the stock when it rejoins the Nasdaq-100, which can add to the swings.

Who this affects

Marketmixed
Medium impact
Traders chasing biotech gains face sharp swings either way.
Companymixed
High impact
Shareholders hold big gains but depend on one drug.
Competitorsneutral
Low impact
BioNTech edged up; Pfizer fell, so peers moved unevenly.
Industrybullish
Medium impact
Personalized cancer drugs gain attention if the results hold.

Moderna vs BioNTech, Pfizer

ModernaMRNA~$204+6.95%+596%~$82B
BioNTechBNTX$97.59+0.7%——
PfizerPFE$27.37-2%——

As of 2026-10-05

How we got here

  1. Moderna and Merck report Phase 3 melanoma trial met its main goal.

  2. Moderna announces October 24 presentation slot at ESMO congress in Madrid.

  3. Citigroup downgrades Moderna to Sell with an $80 price target.

  4. Moderna shares jump about 7% from Friday's $190.01 close.

What to watch

  • Moderna's return to the Nasdaq-100 takes effect, replacing Warner Bros. Discovery.2026-10-09
  • Full Phase 3 melanoma data presented at ESMO, with investor webcast at 1:00 PM EDT.2026-10-24

Educational content only. Not investment advice.

More briefsAll briefs →